|
Asthma
|
0.210 |
Biomarker
|
disease |
RGD |
The expression level of U-II in asthmatic rats was 2.46 +/- 0.15, while in the control group was 1.26 +/- 0.11, the difference being significant (t = 6.236, P < 0.01).
|
17045018 |
2006 |
|
Pulmonary Hypertension
|
0.210 |
AlteredExpression
|
phenotype |
LHGDN |
Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells.
|
15618545 |
2005 |
|
Pulmonary Hypertension
|
0.210 |
Biomarker
|
phenotype |
RGD |
The aim of this study was to investigate the alteration of micro- and ultrapathologic structure, gaseous molecules, and U-II in rats with pulmonary hypertension induced by increased pulmonary blood flow.
|
15042392 |
2004 |
|
Myocardial Reperfusion Injury
|
0.200 |
Biomarker
|
phenotype |
RGD |
Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury.
|
17900760 |
2008 |
|
Cardiomyopathies, Primary
|
0.200 |
Biomarker
|
group |
RGD |
Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy.
|
18280445 |
2008 |
|
Myocardial Diseases, Secondary
|
0.200 |
Biomarker
|
group |
RGD |
Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy.
|
18280445 |
2008 |
|
Cardiomyopathies
|
0.200 |
Biomarker
|
group |
RGD |
Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy.
|
18280445 |
2008 |
|
Endomyocardial Fibrosis
|
0.200 |
Biomarker
|
phenotype |
RGD |
Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.
|
17184580 |
2007 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that UII may participate in macrophage activation and suggest a potential new mechanism underlying atherosclerosis.
|
31360201 |
2019 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis and several other cardiovascular diseases; however, its role in the pathogenesis of AVS remains to be determined.
|
31679703 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urotensin II (UII), a secreted vasoactive peptide hormone, belonging somatostatin superfamily, plays an essential role in atherosclerosis and glucose metabolism.
|
29804270 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the role of macrophage-secreted UII in atherosclerosis progression, and evaluated the therapeutic value of urantide, a potent competitive UII receptor antagonist, in atherosclerosis treatment.
|
31685976 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the role of macrophage-secreted UII in atherosclerosis progression, and evaluated the therapeutic value of urantide, a potent competitive UII receptor antagonist, in atherosclerosis treatment.
|
31685976 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis and several other cardiovascular diseases; however, its role in the pathogenesis of AVS remains to be determined.
|
31679703 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urotensin II (UII), a secreted vasoactive peptide hormone, belonging somatostatin superfamily, plays an essential role in atherosclerosis and glucose metabolism.
|
29804270 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that UII may participate in macrophage activation and suggest a potential new mechanism underlying atherosclerosis.
|
31360201 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis and several other cardiovascular diseases; however, its role in the pathogenesis of AVS remains to be determined.
|
31679703 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Ucn-2 also appears to have potential as a biomarker of diagnostic/prognostic relevance in cardiovascular disease, this being a recent field in the study of this peptide needing further corroboration.
|
31512017 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel insights into the role of urotensin II in cardiovascular disease.
|
31430542 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review will provide an overview of current knowledge about the physiological roles of Uro-II, UCN and AM in the cardiovascular system and their implications in cardiovascular diseases.
|
30481494 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Urotensin II ((U-II)) and its receptor (UTR) are involved in the progression of CVD through enhancement in the production of reactive oxygen species (ROS).
|
29494961 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In previous investigations, U-II receptor antagonists have been shown to protect atherosclerosis in cell and animal models.
|
28363746 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urotensin II and its receptor are thought to be involved in various cardiovascular diseases such as heart failure, pulmonary hypertension and atherosclerosis.
|
28163023 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
UII inhibition has been considered as beneficial strategy for atherosclerosis and restenosis.
|
28173642 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urotensin II and its receptor are thought to be involved in various cardiovascular diseases such as heart failure, pulmonary hypertension and atherosclerosis.
|
28163023 |
2017 |